# PRESERVE-003 (NCT05671510)

> ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05671510
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: OncoC4, Inc.
- Conditions: Non Small Cell Lung Cancer
- Interventions: Gotistobart; Docetaxel
- Enrollment: 630
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=preserve-003-nct05671510